The role of chemotherapy in the treatment of low-grade glioma. A review of the literature

Acta Neurologica Belgica

Volumn 105, Issue 3, 2005, Pages 137-143

  Neyns, Bart ^a   Sadones, Jan ^a   Chaskis, Cristo ^a   de Ridder, Mark ^a   Keyaerts, Marleen ^a   In't Veld, Peter ^a   Michotte, Alex ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Astrocytoma; Chemotherapy; Glioma; Low grade; Oligodendroglioma; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; VINCRISTINE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ASTROCYTOMA; BLEEDING TENDENCY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL TRIAL; DIARRHEA; DNA METHYLATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; GENOME; GENOME ANALYSIS; GLIOMA; GLIOMA CELL; HETEROZYGOSITY LOSS; HUMAN; HYPERSENSITIVITY REACTION; LETHARGY; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; MALIGNANT TRANSFORMATION; METASTASIS; NAUSEA AND VOMITING; NEUROLOGICAL COMPLICATION; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROMOTER REGION; REVIEW; SENSORY NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 26944436693     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Brada M., Hoang-Xuan K. et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol., 2001, 12 (2): 259-66.
2. Brada M., Viviers L. et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol., 2003, 14 (12): 1715-21.
3. Brandes A. A., Ermani M. et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann. Oncol., 2001, 12 (2): 255-7.
4. Buatti J. M., Meeks S. L. et al. Low-grade gliomas: answering one question in a myriad of new questions. J. Clin. Oncol., 2002, 20(9): 2223-4.
5. Buckner J. C., Gesme D. Jr. et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol., 2003, 21 (2): 251-5.
6. Cairncross G., MacDonald D. et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 1994, 12 (10): 2013-21.
7. Cairncross G., Seiferheld W. et al. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02. Journal of Clinical Oncology, Annual Meeting Proceedings (Post-Meeting Edition), 2004, 22 (14S (July 15 Supplement)): 1500.
8. Esteller M., Garcia-Foncillas J. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 2000, 343 (19): 1350-4.
9. Felsberg J., Erkwoh A. et al. Oligodendroglial tumors :refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol., 2004, 14 (2): 121-30.
10. Hegi M. E. Temozolomide targets only glioblastoma with a silenced MGMT-gene. 16th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, 2004.
11. Hegi M. E., Diserens A. C. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352 (10): 997-1003.
12. Hoang-Xuan K., Capelle L. et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol., 2004, 22 (15): 3133-8.
13. Ino Y, Betensky R. A. et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res., 2001, 7 (4): 839-45.
14. Karim A. B., Afra D. et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys., 2002, 52 (2): 316-24.
15. Karim A. B., Maat B. et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int. J. Radiat. Oncol. Biol. Phys., 1996, 36 (3): 549-56.
16. Kaschten B., Stevenaert A. et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J. Nucl. Med., 1998, 39 (5): 778-85.
17. Mason W. R, Krol G. S. et al. Low-grade oligodendroglioma responds to chemotherapy. Neurology, 1996, 46 (1): 203-7.
18. Mollemann M., Wolter M. et al. (2004). "Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer.
19. Ostermann S., Csajka C. et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res., 2004, 10 (11): 3728-36.
20. Pace A., Vidiri A. et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol., 2003, 14 (12): 1722-6.
21. Padma M. V., Said S. et al. Prediction of pathology and survival by FDG PET in gliomas. J. Neurooncol., 2003, 64 (3): 227-37.
22. Paz M. F., Yaya-Tur R. et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res., 2004, 10 (15): 4933-8.
23. Pignatti F., van den Bent M. et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol., 2002, 20 (8): 2076-84.
24. Quinn J. A., Reardon D. A. et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol., 2003, 21 (4): 646-51.
25. Shaw E., Arusell R. et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/ Eastern Cooperative Oncology Group study. J. Clin. Oncol., 2002, 20 (9): 2267-76.
26. Smith J. S., Perry A. et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol., 2000, 18 (3): 636-45.
27. Stege E. M., Kros J. M. et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer, 2005, 103 (4): 802-9.
28. Stupp R., Dietrich P. Y. et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol., 2002, 20(5): 1375-82.
29. Stupp R., Mason W. P. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352 (10): 987-96.
30. van den Bent M. J., Afra D. et al. RT-24, long-term results of trial EORTC 22845/MRC BR4: a randomised trial on the efficacy of radiation therapy (RT) in adult low-grade glioma. Society for Neuro-Oncology Ninth Annual Meeting, Toronto, 2004.
31. van den Bent M. J., Kros J. M. et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology, 1998, 51 (4): 1140-5.
32. Yung W. K., Albright R. E. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer, 2000, 83 (5): 588-93.
33. Weckesser M., Matheja P. et al. Prognostic significance of amino acid transport imaging in patients with brain tumors. Neurosurgery, 2002, 50 (5): 958-64.
34. Yung W. K., Prados M. D. et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol., 1999, 17 (9): 2762-71.